Vivet Therapeutics

Vivet Therapeutics company information, Employees & Contact Information

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Company Details

Employees
19
Founded
-
Address
80, Boulevard Haussmann, Paris,île-De-France 75008,france
Phone
33684755087
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Gene Therapy.
HQ
Paris, Île-de-France
Looking for a particular Vivet Therapeutics employee's phone or email?

Vivet Therapeutics Questions

News

Vivet Therapeutics to Present Key Findings on its Gene - GlobeNewswire

Vivet Therapeutics to Present Key Findings on its Gene GlobeNewswire

Wilson Disease Market Size to Reach USD 440.2 Million by 2035, Impelled by Surging Prevalence with Advanced Diagnostic Techniques - BioSpace

Wilson Disease Market Size to Reach USD 440.2 Million by 2035, Impelled by Surging Prevalence with Advanced Diagnostic Techniques BioSpace

Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease - Healio

Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease Healio

Vivet wins $5.3m grant to develop gene therapy for rare metabolic disorder - Clinical Trials Arena

Vivet wins $5.3m grant to develop gene therapy for rare metabolic disorder Clinical Trials Arena

French Gene Therapy for Wilson’s Disease gets Orphan Status - Labiotech.eu

French Gene Therapy for Wilson’s Disease gets Orphan Status Labiotech.eu

Pfizer to make Vivet’s Wilson disease gene therapy for Phase I/II trial - BioProcess International

Pfizer to make Vivet’s Wilson disease gene therapy for Phase I/II trial BioProcess International

On the Fast Track to a More Targeted Treatment for Rare Disease - Pfizer

On the Fast Track to a More Targeted Treatment for Rare Disease Pfizer

European Commission grants orphan drug designation for Vivet’s VTX-806 - PharmaTimes

European Commission grants orphan drug designation for Vivet’s VTX-806 PharmaTimes

Pfizer Gains Option to Buy Rare Disease Gene Therapy Developer Vivet for Up to $687M - Genetic Engineering and Biotechnology News

Pfizer Gains Option to Buy Rare Disease Gene Therapy Developer Vivet for Up to $687M Genetic Engineering and Biotechnology News

Pfizer visits Vivet with $51m - - Global Venturing

Pfizer visits Vivet with $51m - Global Venturing

Design of a promising gene therapy method to treat Wilson's disease - EurekAlert!

Design of a promising gene therapy method to treat Wilson's disease EurekAlert!

Considerations for Effectively Managing Wilson Disease, with Michael Schilsky, MD - HCPLive

Considerations for Effectively Managing Wilson Disease, with Michael Schilsky, MD HCPLive

Pfizer injects $500M more into gene therapy manufacturing - BioPharma Dive

Pfizer injects $500M more into gene therapy manufacturing BioPharma Dive

Pfizer drops Beqvez, leaving its gene therapy cupboard bare - pharmaphorum

Pfizer drops Beqvez, leaving its gene therapy cupboard bare pharmaphorum

AstraZeneca's $39B Alexion buyout bears fruit, yielding late-phase win for potential blockbuster rare disease drug - Fierce Biotech

AstraZeneca's $39B Alexion buyout bears fruit, yielding late-phase win for potential blockbuster rare disease drug Fierce Biotech

DNA maker Touchlight adds Lonza manufacturing vet as it swings at COVID-19 vaccine, cell and gene therapy markets - Fierce Pharma

DNA maker Touchlight adds Lonza manufacturing vet as it swings at COVID-19 vaccine, cell and gene therapy markets Fierce Pharma

Paediatric research sets new standards for therapy in paediatric and adult cholestasis - The Lancet

Paediatric research sets new standards for therapy in paediatric and adult cholestasis The Lancet

Pfizer goes big on gene therapy with $500m facility spend - PMLiVE

Pfizer goes big on gene therapy with $500m facility spend PMLiVE

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ GlobeNewswire

Corporates visit Vivet for $41m series A - - Global Venturing

Corporates visit Vivet for $41m series A - Global Venturing

Progressive Familial Intrahepatic Cholestasis (PFIC) Market - openPR.com

Progressive Familial Intrahepatic Cholestasis (PFIC) Market openPR.com

FierceBiotech's 2017 Fierce 15 - Fierce Biotech

FierceBiotech's 2017 Fierce 15 Fierce Biotech

GCV Powerlist 2017: Reinhard Ambros - - Global Venturing

GCV Powerlist 2017: Reinhard Ambros - Global Venturing

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant